Abstract: The cannabinoid receptor type 2 (CB2) has a very low expression level in brain tissue under basal conditions, but it is up-regulated in diverse pathological conditions. Two promising lead structures from the literature, N-((3S,5S,7S)-adamantan-1-yl)-8-methoxy-4-oxo-1-pentyl-1,4-dihydroquinoline-3-carboxamide and 8-butoxy-N-(2-fluoro-2-phenylethyl)-7-methoxy-2-oxo-1,2-dihydroquinoline-3-carboxamide -designated KD2 and KP23, respectively -were evaluated as potential PET ligands for imaging CB2. Both KD2 and KP23 were synthesized and labeled with carbon-11. In vitro autoradiographic studies on rodent spleen tissues showed that [(11)C]KD2 exhibits superior properties. A pilot study using [(11)C]KD2 on human post mortem ALS spinal cord slices indicated high CB2 expression level and specific binding, a very exciting finding if considering the future diagnostic application of CB2 ligands and their utility in therapy monitoring. In vivo blocking studies in rats with [(11)C]KD2 showed also high specific uptake in spleen tissue. Although the protein-bound fraction is relatively high, KD2 or KD2 derivatives could be very useful tools for the non-invasive investigation of CB2 levels under various neuroinflammatory conditions. 
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Introduction
Cannabinoid receptor types 1 (CB1) and 2 (CB2) were discovered about 30 years ago as G protein-coupled receptors containing seven transmembrane spanning domains. CB1 is expressed throughout the body, but mainly in brain regions (cerebellum, basal ganglia, hippocampus, and neocortex). CB2 is predominantly expressed on cells related to the immune system (spleen, lymphocytes) and also on keratinocytes. The presence of CB2 in the central nervous system has been controversially discussed in literature since 1996. [1] Today CB2 is generally accepted to be present in brain tissues, although in very low concentrations.
However, under neuroinflammatory conditions, a CB2 level increase is observed. For instance in the brain of Alzheimer patients where activated microglia cluster at β-amyloid plaques. [2] [3] [4] [5] CB2 increase is also reported for the rat chronic lesion model of Huntington's disease, especially in the striatum. [6] Furthermore, both hypoxia-ischemia and middle cerebral artery occlusion induced an up-regulation in the expression of CB2 in proliferating microglia in rat brain. [7] Increased CB2 levels were also reported in post mortem spinal cord of human patients of Amyotrophic Lateral Sclerosis (ALS) and corresponding mouse models and Multiple Sclerosis. [4, 8] A large number of structurally diverse CB2 ligands have been synthesized and characterized in the past decade. [9] Among all these classes of CB2 ligands, 2-oxoquinoline and 4-quinolone-3-carboxamide derivatives appear to be the most efficient inverse agonists, with high binding affinity and selectivity towards CB2. Currently, there are no PET (positron emission tomography) ligands for imaging CB2 expression in humans. A suitable PET radioligand for imaging CB2 would be an invaluable research tool to explore the role of CB2 receptor expression in peripheral and/or central inflammatory disorders.
Herein, we report the in vitro/in vivo evaluation of two oxo-quinoline derivatives, designated [ 
Synthesis and Radiolabeling

Synthesis of KD2
The synthesis of the reference compound, KD2, followed synthetic pathways already described. [10] In brief, the quinoline structure 2 was prepared via the Gould-Jacobs reaction as outlined in Scheme 1 by reacting anisidine with diethyl 2-(ethoxymethylene)malonate and subsequent benzannulation at high temperature. N-alkylation with 1-bromopentane followed by hydrolysis of the ethyl ester gave the free quinoline acid 4, which was coupled to aminoadamantane using HBTU as the coupling reagent to yield KD2. Phenolic precursor compound 5 for radiolabeling was synthesized from the reference compound by demethylation using boron tribromide.
Synthesis of KP23
The synthesis of the non-radioactive reference compound, KP23, was accomplished based on the modified procedure described by Turkman et al. [11] as outlined in Scheme 2. Briefly, compound 7 was obtained by aromatic nitration of 3-hydroxy-4-methoxybenzaldehyde (6) with nitric acid. O-alkylation with 1-bromobutane afforded intermediate 8. Reduction using iron powder followed by reaction in situ with dimethyl malonate yielded compound 9. Hydrolysis under basic conditions to the free acid 10 and amide bond formation using 2-fluoro-2-phenylethanamine free base led to the final reference compound KP23. The phenolic precursor 11 for radiolabeling was directly synthesized from KP23 by demethylation using lithium chloride.
Radiolabeling Procedure
The phenolic precursor 5 or 11, was reacted with [ 
in vitro/in vivo Evaluation
Autoradiography Experiments
To confirm specificity of binding of the radiotracers, rat and mouse spleens known to have a high physiological expression of CB2 were investigated in autoradiography experiments (Fig. 1) In a preliminary autoradiographic study, we investigated whether [ 11 C]KD2 binds to human post mortem ALS spinal cord slices, as literature reports suggest CB2 overexpression in the spinal cord of ALS patients. [12] [13] [14] Fig. 2 confirms not only the presence of CB2 but also specific binding of [ To exclude KD2 as a substrate for efflux transporter P-gp within the blood brain barrier, the permeation of [ 
MDCK cells transfected with human P-gp was investigated. The respective ratio for [
11 C]KD2 of the transport basal to apical and apical to basal, respectively, was 0.5, indicating no net efflux transport by P-gp. Lipophilicity (logD) as an important physicochemical attribute for a CNS penetrating compound was determined by the shake-flask method in octanol/buffer at pH 7.4. [15] The logD value of [ 11 C]KD2 was found to be 3.29 ± 0.04 (n = 6), and suggested that [ 
in vivo PET studies
PET scans with Wistar rats showed high accumulation of [ 11 C]KD2 in liver, spleen and intestine. The accumulation in spleen was displaced by injection of the CB2 specific partial agonist GW405833 (1.5 mg/kg), indicating in vivo specific binding (Fig. 3) . As expected, radioactivity in the brain was significantly lower than in the periphery (data not shown). Uptake in pons and cerebellum was higher than in hippocampus and caudate/putamen, in agreement with the expression pattern of CB2 in the rat brain. [16] [17] [18] We are currently investigating the utility of [ 11 C]KD2 in mouse models of neuroinflammation where CB2 receptors are upregulated, e.g. the lipopolysaccharide LPS mouse model as described by Qin et al. [19, 20] 
Conclusion
In the process of developing a suitable CNS radiotracer for imaging CB2 receptors we evaluated the potential of two lead compounds KD2 and KP23. We have established the syntheses of non-radioactive reference compounds using modified synthetic routes based on literature procedures. A robust and reliable radiosynthetic procedure for both novel CB2 radiotracers, [ 
